Thursday’s Midday Movers: Peabody Energy Comm (BTU), Recro Pharma (REPH), Rite Aid (RAD), Dynavax (DVAX), TG Therapeutics (TGTX)

So far Thursday, January 2, NASDAQ is down -0.41% and the S&P is down -0.34%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Peabody Energy Comm (BTUResearch Report), Recro Pharma (REPHResearch Report), Rite Aid (RADResearch Report), Dynavax (DVAXResearch Report) and TG Therapeutics (TGTXResearch Report).

Peabody Energy Comm is up 8.24% in midday trading to $10.05. Shares opened today at $9.28. The company has a 52-week low of $8.65 and a 52-week high of $35.11. On the Street’s front, the average 12-month analyst price target for the stock is $16.33, marking a 75.97% potential upside from current levels. In a report issued on December 24, B.Riley FBR analyst Lucas Pipes maintained a Hold rating on BTU, with a price target of $11.00, which represents a potential upside of 19% from where the stock is currently trading. Separately, on October 30, Deutsche Bank’s Chris Terry maintained a Buy rating on the stock and has a price target of $24.00. In the last 30 days, insiders purchased $67.95K worth of BTU shares.

Recro Pharma is down -6.42% in midday trading to $17.28. Shares opened today at $18.46. The company has a 52-week low of $5.53 and a 52-week high of $19.00. On the Street’s front, the average 12-month analyst price target for the stock is $20.50, marking a 11.05% potential upside from current levels. In a report issued on November 26, Stephens Inc analyst Jacob Johnson maintained a Buy rating on REPH, with a price target of $19.00, which represents a slight upside potential from current levels.

Rite Aid is down -6.28% in midday trading to $16.26. Shares opened today at $17.35. The company has a 52-week low of $5.04 and a 52-week high of $23.88. On the Street’s front, the average 12-month analyst price target for the stock is $12.00, marking a -30.84% potential downside from current levels. In a report issued on December 23, Deutsche Bank analyst George Hill maintained a Sell rating on RAD, with a price target of $12.00, which implies a downside of 31% from current levels. In the last 30 days, insiders have sold $31.04K worth of RAD shares and purchased $499.7K worth of RAD shares.

See today’s analyst top recommended stocks >>

Dynavax is down -5.9% in midday trading to $5.42. Shares opened today at $5.76. The company has a 52-week low of $2.60 and a 52-week high of $12.42. On the Street’s front, the average 12-month analyst price target for the stock is $16.50, marking a 186.46% potential upside from current levels. In a report issued on December 3, William Blair analyst Matt Phipps maintained a Buy rating on DVAX.

TG Therapeutics is down -4.95% in midday trading to $10.56. Shares opened today at $11.11. The company has a 52-week low of $3.87 and a 52-week high of $11.42. On the Street’s front, the average 12-month analyst price target for the stock is $18.50, marking a 66.52% potential upside from current levels. In a report issued on December 10, H.C. Wainwright analyst Edward White reiterated a Buy rating on TGTX, with a price target of $20.00, which implies an upside of 80% from current levels.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.